Cargando…
A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model
The COVID-19 pandemic has generated intense interest in the rapid development and evaluation of vaccine candidates for this disease and other emerging diseases. Several novel methods for preparing vaccine candidates are currently undergoing clinical evaluation in response to the urgent need to preve...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8066708/ https://www.ncbi.nlm.nih.gov/pubmed/33916180 http://dx.doi.org/10.3390/vaccines9040340 |
_version_ | 1783682632067842048 |
---|---|
author | Ragan, Izabela K Hartson, Lindsay M Dutt, Taru S Obregon-Henao, Andres Maison, Rachel M Gordy, Paul Fox, Amy Karger, Burton R Cross, Shaun T Kapuscinski, Marylee L Cooper, Sarah K Podell, Brendan K Stenglein, Mark D Bowen, Richard A Henao-Tamayo, Marcela Goodrich, Raymond P |
author_facet | Ragan, Izabela K Hartson, Lindsay M Dutt, Taru S Obregon-Henao, Andres Maison, Rachel M Gordy, Paul Fox, Amy Karger, Burton R Cross, Shaun T Kapuscinski, Marylee L Cooper, Sarah K Podell, Brendan K Stenglein, Mark D Bowen, Richard A Henao-Tamayo, Marcela Goodrich, Raymond P |
author_sort | Ragan, Izabela K |
collection | PubMed |
description | The COVID-19 pandemic has generated intense interest in the rapid development and evaluation of vaccine candidates for this disease and other emerging diseases. Several novel methods for preparing vaccine candidates are currently undergoing clinical evaluation in response to the urgent need to prevent the spread of COVID-19. In many cases, these methods rely on new approaches for vaccine production and immune stimulation. We report on the use of a novel method (SolaVAX) for production of an inactivated vaccine candidate and the testing of that candidate in a hamster animal model for its ability to prevent infection upon challenge with SARS-CoV-2 virus. The studies employed in this work included an evaluation of the levels of neutralizing antibody produced post-vaccination, levels of specific antibody sub-types to RBD and spike protein that were generated, evaluation of viral shedding post-challenge, flow cytometric and single cell sequencing data on cellular fractions and histopathological evaluation of tissues post-challenge. The results from this preliminary evaluation provide insight into the immunological responses occurring as a result of vaccination with the proposed vaccine candidate and the impact that adjuvant formulations, specifically developed to promote Th1 type immune responses, have on vaccine efficacy and protection against infection following challenge with live SARS-CoV-2. This data may have utility in the development of effective vaccine candidates broadly. Furthermore, the results of this preliminary evaluation suggest that preparation of a whole virion vaccine for COVID-19 using this specific photochemical method may have potential utility in the preparation of one such vaccine candidate. |
format | Online Article Text |
id | pubmed-8066708 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80667082021-04-25 A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model Ragan, Izabela K Hartson, Lindsay M Dutt, Taru S Obregon-Henao, Andres Maison, Rachel M Gordy, Paul Fox, Amy Karger, Burton R Cross, Shaun T Kapuscinski, Marylee L Cooper, Sarah K Podell, Brendan K Stenglein, Mark D Bowen, Richard A Henao-Tamayo, Marcela Goodrich, Raymond P Vaccines (Basel) Article The COVID-19 pandemic has generated intense interest in the rapid development and evaluation of vaccine candidates for this disease and other emerging diseases. Several novel methods for preparing vaccine candidates are currently undergoing clinical evaluation in response to the urgent need to prevent the spread of COVID-19. In many cases, these methods rely on new approaches for vaccine production and immune stimulation. We report on the use of a novel method (SolaVAX) for production of an inactivated vaccine candidate and the testing of that candidate in a hamster animal model for its ability to prevent infection upon challenge with SARS-CoV-2 virus. The studies employed in this work included an evaluation of the levels of neutralizing antibody produced post-vaccination, levels of specific antibody sub-types to RBD and spike protein that were generated, evaluation of viral shedding post-challenge, flow cytometric and single cell sequencing data on cellular fractions and histopathological evaluation of tissues post-challenge. The results from this preliminary evaluation provide insight into the immunological responses occurring as a result of vaccination with the proposed vaccine candidate and the impact that adjuvant formulations, specifically developed to promote Th1 type immune responses, have on vaccine efficacy and protection against infection following challenge with live SARS-CoV-2. This data may have utility in the development of effective vaccine candidates broadly. Furthermore, the results of this preliminary evaluation suggest that preparation of a whole virion vaccine for COVID-19 using this specific photochemical method may have potential utility in the preparation of one such vaccine candidate. MDPI 2021-04-01 /pmc/articles/PMC8066708/ /pubmed/33916180 http://dx.doi.org/10.3390/vaccines9040340 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ragan, Izabela K Hartson, Lindsay M Dutt, Taru S Obregon-Henao, Andres Maison, Rachel M Gordy, Paul Fox, Amy Karger, Burton R Cross, Shaun T Kapuscinski, Marylee L Cooper, Sarah K Podell, Brendan K Stenglein, Mark D Bowen, Richard A Henao-Tamayo, Marcela Goodrich, Raymond P A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model |
title | A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model |
title_full | A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model |
title_fullStr | A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model |
title_full_unstemmed | A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model |
title_short | A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model |
title_sort | whole virion vaccine for covid-19 produced via a novel inactivation method and preliminary demonstration of efficacy in an animal challenge model |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8066708/ https://www.ncbi.nlm.nih.gov/pubmed/33916180 http://dx.doi.org/10.3390/vaccines9040340 |
work_keys_str_mv | AT raganizabelak awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT hartsonlindsaym awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT dutttarus awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT obregonhenaoandres awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT maisonrachelm awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT gordypaul awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT foxamy awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT kargerburtonr awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT crossshaunt awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT kapuscinskimaryleel awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT coopersarahk awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT podellbrendank awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT stengleinmarkd awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT bowenricharda awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT henaotamayomarcela awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT goodrichraymondp awholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT raganizabelak wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT hartsonlindsaym wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT dutttarus wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT obregonhenaoandres wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT maisonrachelm wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT gordypaul wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT foxamy wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT kargerburtonr wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT crossshaunt wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT kapuscinskimaryleel wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT coopersarahk wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT podellbrendank wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT stengleinmarkd wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT bowenricharda wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT henaotamayomarcela wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel AT goodrichraymondp wholevirionvaccineforcovid19producedviaanovelinactivationmethodandpreliminarydemonstrationofefficacyinananimalchallengemodel |